(Reuters) -Bristol Myers Squibb said on Monday that it was planning to launch its schizophrenia treatment, Cobenfy, in the UK in 2026 and that the pricing would be similar to its U.S. list price.
The drug carries a list price of $1,850 a month or about $22,500 annually in the United States.
Bristol said it planned to submit a marketing authorisation application for Cobenfy to the UK medicines regulator later this year, under a fast-track route.
The drug gained U.S. FDA approval last year and became the first approved antipsychotic that targets cholinergic receptors as opposed to dopamine receptors, which have long been the standard of care.
(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber and Anil D’Silva)
Comments